Warning Letter Record: Safrel Pharmaceuticals LLC (2026-08-07) — CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
In short: The FDA Center for Drug Evaluation and Research issued Warning Letter 320-26-111 on August 7, 2026, to Safrel Pharmaceuticals LLC (FEI 3042030663) in Dayton, New Jersey, following a January 13–30, 2026 inspection. The letter cites significant CGMP violations for finished OTC drugs, including: failure to establish an adequate quality unit with written procedures and oversight; absence of quality agreements and Certificates of Analysis from suppliers; improper product segregation in warehousing; and lack of lot-level traceability for distribution and recall purposes. The FDA found the firm's February 22, 2026 response inadequate and demands a comprehensive remediation plan addressing quality unit authority, supplier qualification, batch review procedures, and product traceability within a specified timeframe.
Argus analysis
# FDA Warning Letter Analysis: Safrel Pharmaceuticals LLC
**Company and Findings**
Safrel Pharmaceuticals LLC, a finished pharmaceutical manufacturer in Dayton, New Jersey, received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on August 7, 2026, following an inspection conducted January 13–30, 2026. FDA investigators identified significant violations of Current Good Manufacturing Practice (CGMP) regulations, rendering the company's over-the-counter drug products adulterated under federal law. The inspection documented critical gaps in quality oversight, supplier management, warehouse controls, and product traceability—systemic deficiencies that exceeded typical documentation lapses.
**Regulatory Citations and Meaning**
The warning references 21 CFR parts 210 and 211, the foundational CGMP standards for finished pharmaceuticals. Specific violations cite 21 CFR 211.22(a) and (d), which require firms to establish a quality unit with documented authority, responsibility, and written procedures. FDA also cited 21 CFR 211.42 regarding product receipt, quarantine, storage, and release procedures. These sections require manufacturers to implement controls ensuring drug products meet specifications before distribution. The letter emphasizes that Safrel lacked written quality agreements with suppliers, failed to obtain Certificates of Analysis for incoming products, and maintained inadequate segregation of labeled, unlabeled, and expired materials—violations indicating absent foundational quality infrastructure rather than isolated procedural gaps.
**Response Timeline and Industry Watch Points**
Safrel's February 22, 2026 response proved inadequate; FDA found it lacked comprehensive root-cause analysis, implementation timelines, and risk assessment details. The warning demands remediation addressing quality unit authority, supplier qualification, warehousing procedures, documentation systems, and lot traceability. Compliance officers monitoring similar firms should note that FDA explicitly recommended engaging a qualified CGMP consultant under 21 CFR 211.34. Peers should watch for potential seizure or injunction actions if Safrel fails to demonstrate prompt, substantive corrective measures. The letter's emphasis on contract manufacturer oversight signals intensified FDA scrutiny of firms using third-party packagers and manufacturers without adequate quality controls.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Safrel Pharmaceuticals LLC MARCS-CMS 730520 — August 07, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA EMAIL WITH READ RECEIPT Reference #: 320-26-111 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Mr. Dipen Patel Recipient Title Chief Executive Officer Safrel Pharmaceuticals LLC 178 Ridge Road Dayton , NJ 08810-2532 United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-111 August 7, 2026 Dear Mr. Patel: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Safrel Pharmaceuticals LLC, FEI 3042030663, at 178 Ridge Road, Dayton, New Jersey, from January 13 to January 30, 2026. This Warning Letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations, parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your February 22, 2026, response to our Form FDA 483 in detail. During our inspection, our investigators observed specific violations, including but not limited to the following: 1. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality unit are not in writing and fully followed (21 CFR 211.22(a) and 21 CFR 211.22(d)). Your firm, which holds, labels 1 , releases, and distributes over the counter (OTC) drug products under your own label (b)(4) , lacks adequate quality unit (QU) oversight and procedures for the drug products you distribute. During the inspection, you stated that no QU oversight is performed for your suppliers and contract manufacturers, including packagers. Specific failures observed during the inspection include but are not limited to the following: The absence of procedures describing how you ensure that the drug products you receive meet quality specifications, and the roles and responsibilities of each party for each of your suppliers (for example, quality agreements). Also, you do not request, receive, or maintain Certificates of Analysis (CoAs) for incoming bulk and finished OTC drug products. Notably, one of your contract manufacturers, (b)(4) , has been considered noncompliant with CGMP across multiple FDA inspections. Improper segregation of drug products throughout your warehouse to prevent mix-ups. For example, boxes of finished drug products designated as “Unlabeled, No Lot, No Exp” were observed to contain unlabeled, filled product containers stored in the same general area as labeled drug products. Your firm has no written procedures describing how finished drug products are to be receiv…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- When did FDA issue the warning letter to Safrel Pharmaceuticals LLC?
- FDA issued the letter (MARCS-CMS 730520) on 2026-08-07 and posted it publicly on fda.gov on 2026-08-18.
- Is the FDA warning letter to Safrel Pharmaceuticals LLC publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/safrel-pharmaceuticals-llc-730520-08072026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Warning Letter Record: Safrel Pharmaceuticals LLC (2026-08-07) — CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-safrel-pharmaceuticals-llc-2026-08-07-cgmp
"Warning Letter Record: Safrel Pharmaceuticals LLC (2026-08-07) — CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-safrel-pharmaceuticals-llc-2026-08-07-cgmp.
Argus HQ Research. "Warning Letter Record: Safrel Pharmaceuticals LLC (2026-08-07) — CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire Holdings LLC. Accessed August 19, 2026. https://argushq.ai/fda/warning-letter/fda-wl-safrel-pharmaceuticals-llc-2026-08-07-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_safrel_pharmaceuticals_llc_2026_08_07_cgmp_2026,
title = {Warning Letter Record: Safrel Pharmaceuticals LLC (2026-08-07) — CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-safrel-pharmaceuticals-llc-2026-08-07-cgmp},
note = {Accessed: August 19, 2026}
}